Edoxaban Management in Diagnostic and Therapeutic Procedures
Phase of Trial: Phase IV
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation; Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions
- Acronyms EMIT-AF/VTE
- Sponsors Daiichi Sankyo Inc
- 02 Jan 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2018.
- 08 Dec 2016 According to a Daiichi Sankyo Company media release, first patient has been enrolled in this trial.